Salud financiera de hoja de balance de Krystal Biotech
Salud financiera controles de criterios 6/6
Krystal Biotech has a total shareholder equity of $778.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $818.4M and $39.7M respectively.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
Ratio de cobertura de intereses | n/a |
Efectivo | US$532.18m |
Patrimonio | US$778.64m |
Total pasivo | US$39.71m |
Activos totales | US$818.36m |
Actualizaciones recientes sobre salud financiera
We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Recent updates
Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth
Jun 17Krystal Biotech EPS misses by $0.16
May 10Krystal Biotech provides update on pivotal GEM-3 study of B-VEC for DEB
Apr 26Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Mar 02Krystal Biotech secures $125 capital via equity raise
Feb 03Krystal Biotech lays out catalysts for 2021
Jan 07Análisis de la situación financiera
Pasivos a corto plazo: KRYS's short term assets ($587.9M) exceed its short term liabilities ($33.1M).
Pasivo a largo plazo: KRYS's short term assets ($587.9M) exceed its long term liabilities ($6.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: KRYS is debt free.
Reducción de la deuda: KRYS had no debt 5 years ago.
Cobertura de la deuda: KRYS has no debt, therefore it does not need to be covered by operating cash flow.
Cobertura de intereses: KRYS has no debt, therefore coverage of interest payments is not a concern.